Peripheral Neuropathy Market Insights, Analysis, Trends and Opportunities 2023 - 2032
The Peripheral Neuropathy Market Size is expected to reach USD 7.4 Billion by 2032 at 9 % CAGR during the
forecast period 2023-2032.
The extensive study for diabetic peripheral neuropathy epidemiology to
discover economic treatment and expansion of peripheral nerve repair devices
market can aid the peripheral neuropathy market size to increase by 2032.
Damaged nerves in hands, arms, and feet due to causes, such as; chemotherapy
treatments and diabetes require immediate attention. The increase in awareness
about peripheral neuropathy and its therapy are innovations in the field can
add impetus to the market.
Major Key
Players:
Bristol Myers Squibb (US), Novartis AG (UK), Abbott Laboratories (US),
Pfizer Inc (US), Merck and Co. Inc. (US), GlaxoSmithKline plc (UK), F.
Hoffmann-La Roche Ltd. (UK), Eli Lilly and Company (US), Cipla Limited (India),
Lupin Limited (India), RxFunction, Inc. (US), and Dr. Reddy's Laboratories
(India) among others are some Key Peripheral Neuropathy Market
Players
that are studied by MRFR.
Peripheral
Neuropathy Market Insights and Forecast By Type (Diabetic
Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic
Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy), Treatment
(Pharmacological Therapies, Non-Pharmacological Therapies, Others) and End-User
(Hospitals and Clinics, Ambulatory Centers, Others) - Forecast to 2032
Segment Analysis
The segment
evaluation of the global Peripheral Neuropathy Market is based on end user,
type, and treatment.
The type-based
segments of the peripheral neuropathy market are idiopathic peripheral
neuropathy, diabetic peripheral neuropathy (DPN), HIV/AIDS-associated peripheral neuropathy, and chemotherapy-induced peripheral
neuropathy (CIPN). The segment of diabetic peripheral neuropathy (DPN) can
surge as the prevalence of diabetic peripheral neuropathy among the youth with
diabetes populace is observed to increase. Top-notch institutes are
experimenting with safety and efficacy of latest chemotherapy-induced
peripheral neuropathy (CIPN) treatment solutions. chemotherapeutic agents, such
as; epothilones, vinca alkaloids, platinum drugs, taxanes, lenolidamide, and
bortezomib among others are used to treat CIPN. The easy availability of these
natural therapeutic moiety and increase in demand for CIPN treatment to can
support market progress.
The
treatment-based segments of the global peripheral neuropathy market are
non-pharmacological therapies, and pharmacological therapies among others. The
pharmacological therapies segment is expected to hold the majority share of the
market owing to the Pharmacological therapies are primary in the peripheral
neuropathy therapy and the availability of different non-pharmacological
therapies can favor expansion of the market in the near future.
The end
users-based segments of the peripheral neuropathy market are ambulatory
centers, and hospitals and clinics among others. The hospitals and clinics
segment can acquire the largest share of the worldwide market. The rise in
awareness about different advanced treatments introduced in hospitals and
expertise can benefit the market. The ambulatory centers segment can thrive
owing to the easy availability of advanced medical technology and specialized
medical services.
Regional Analysis
The peripheral neuropathy market is assessed across the Americas, the
Middle East & Africa, Europe, and Asia Pacific. The Americas the peripheral
neuropathy market can secure the largest share of the worldwide market in the
near future. The growing amount of per capita healthcare expenditure and surge
in cases of peripheral neuropathy market can impact the market in the Americas.
Latin America and North America are studied extensively to understand the
market dynamics. The US can rise at high pace. In Europe, peripheral neuropathy
market can expand exponentially due to increase in need for economic and
convenient neuropathy treatment. Asia Pacific peripheral neuropathy market can
surge owing to presence of top notch therapeutic companies in the region. The
rise in geriatric population and diabetic patient can support expansion of the
regional market. Asia Pacific can thrive in the worldwide market at rapid pace.
The peripheral neuropathy market in MEA can grow at moderate pace.
About Market Research
Future
At Market Research Future (MRFR), we enable our
customers to unravel the complexity of various industries through our Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide the
optimum quality market research and intelligence services to our clients. Our
market research studies by products, services, technologies, applications, end
users, and market players for global, regional, and country level market
segments, enable our clients to see more, know more, and do more, which help to
answer all their most important questions.
In order to stay updated with technology and work
process of the industry, MRFR often plans & conducts meet with the industry
experts and industrial visits for its research analyst members.
Contact us:
Market Research Future
(part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 646 845 9312
Comments
Post a Comment